Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers

DISEASE CHARACTERISTICS: * Histologically confirmed primary lung carcinoma * Non-squamous histology * Advanced disease defined as stage IIIB disease with cytologically documented malignant pleural or pericardial effusion or stage IV disease * Available pathology block or unstained slides from initial or subsequent diagnosis * Must have undergone ≥ 1 core biopsy * No patients whose diagnosis was made through a fine-needle aspirate * No uncontrolled pleural effusions, ascites, or third-space fluid collections * Meets 1 of the following criteria: * Non-smoker, defined as patients who smoked ≤ 100 cigarettes in their lifetime * Former light smoker, defined as patients who smoked between \> 100 cigarettes AND ≤ 10 pack-years AND quit ≥ 1 year ago * No known central nervous system disease, except for treated brain metastases meeting the following criteria: * No evidence of progression or hemorrhage after treatment * No ongoing requirement for dexamethasone as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period * Stable doses of anticonvulsants are allowed * Treatment for brain metastases may include whole-brain radiotherapy, radiosurgery (gamma knife, LINAC, or equivalent), or a combination as deemed appropriate by the treating physician * No patients with central nervous system (CNS) metastases treated by neurosurgical resection * No brain biopsy within the past 3 months PATIENT CHARACTERISTICS: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Absolute neutrophil count (ANC) ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * Aspartate aminotransferase (AST/ALT) ≤ 2.5 times ULN * Calculated creatinine clearance \> 45 mL/min OR creatinine ≤ 1.5 times ULN * Prothrombin time ≤ 1.5 times ULN * Partial thromboplastin time ≤ ULN * Urine protein:creatinine ratio ≤ 1.0 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Patients with a history of hypertension are eligible provided it is well controlled (BP \< 150/100 mm Hg) on a stable regimen of antihypertensive therapy * No history of hypertensive crisis or hypertensive encephalopathy * Able and compliant with folic acid and B12 supplementation * Able to swallow tablets intact or dissolved in water * No dysphagia or active gastrointestinal (GI) disease or disorder that alters GI motility or absorption * No lack of integrity of the GI tract (e.g., a significant surgical resection of the stomach or small bowel) * No abdominal fistula, GI perforation, or intraabdominal abscess within the past 6 months * None of the following: * Ongoing or active infection * Symptomatic congestive heart failure (NYHA class II-IV) * Cardiac arrhythmia * Psychiatric illness, social situations, or any other medical condition that would limit compliance with study requirements * No myocardial infarction or other evidence of arterial thrombotic disease (angina) within the past 6 months * No history of cerebral vascular accident or transient ischemic attack within the past 6 months * No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within the past 6 months * No history of bleeding diathesis or coagulopathy * No ongoing hemoptysis, defined as ≥ ½ teaspoon of bright red blood * Patients with procedure-related hemoptysis that has resolved post-procedure are eligible * No serious nonhealing wound, ulcer, bone fracture, or significant traumatic injury within the past 28 days * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies PRIOR CONCURRENT THERAPY: * No prior chemotherapy * Patient must be chemotherapy naive * Prior neoadjuvant or adjuvant chemotherapy allowed provided it was completed ≥ 6 months ago * No prior anti-vascular endothelial growth factor therapy * At least 3 weeks since prior major surgery * At least 1 week since prior radiotherapy * More than 28 days since prior and no concurrent treatment with an investigational agent * More than 7 days since prior core biopsy * Concurrent daily treatment with aspirin or NSAIDs are eligible provided patients are able to interrupt NSAIDs 2 days before (5 days for long-acting NSAIDs), the day of, and for 2 days following the administration of pemetrexed disodium * No concurrent treatment with dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix), and/or cilostazol (Pletal)